CD28 and neoplasm: CTLA4 inhibition acts at the T-cell–antigen-presenting cell immune synapse by promoting unopposed interactions of B7 costimulatory ligands with CD28, leading to increased activation of naive CD4+ and CD8+ T cells and rebalancing of the effector and regulatory compartments within the tumor microenvironment (TME) (15, 16).